menu
    • menu
    [{"orgOrder":0,"company":"Rallybio","sponsor":"Pivotal bioVenture Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Series B Financing","leadProduct":"RLYB211","moa":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Rallybio \/ Pivotal bioVenture Partners","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Pivotal bioVenture Partners"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"RLYB211","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Not Applicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"RLYB211","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Not Applicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"RLYB211","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Not Applicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"RLYB331","moa":"Matriptase-2","graph1":"Hematology","graph2":"Preclinical","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rallybio \/ Rallybio Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Rallybio \/ Rallybio Corporation"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"RLYB116","moa":"Completent C5","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Not Applicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Rallybio \/ Rallybio","highestDevelopmentStatusID":"3","companyTruncated":"Rallybio \/ Rallybio"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"RLYB212","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Not Applicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"EyePoint Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"RLYB114","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Rallybio \/ Rallybio","highestDevelopmentStatusID":"4","companyTruncated":"Rallybio \/ Rallybio"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"RLYB212","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Not Applicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"RLYB211","moa":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Not Applicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"RLYB212","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Not Applicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"RLYB116","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Not Applicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"RLYB212","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Not Applicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"RLYB212","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Rallybio","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"","sponsorNew":"Rallybio \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"RLYB212","moa":"","graph1":null,"graph2":null,"graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Rallybio \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Rallybio

    Menu

    Rallybio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rallybio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Rallybio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLYB212

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

                            Details : RLYB212, an anti-HPA-1a monoclonal antibody and once monthly subcutaneous administration, being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia.

                            Brand Name : RLYB212

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 21, 2024

                            Lead Product(s) : RLYB212

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rallybio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Rallybio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLYB212

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : $6.6 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Rallybio Collaborates on Solutions for Fetal Alloimmune Thrombocytopenia

                            Details : Under this collaboration, Johnson & Johnson will fund Rallybio's RLYB212, the sole investigational therapy aimed at addressing the needs of pregnant individuals at risk of FNAIT.

                            Brand Name : RLYB212

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 10, 2024

                            Lead Product(s) : RLYB212

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : $6.6 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Rallybio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Rallybio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLYB116

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously ...

                            Details : RLYB116 is a novel antibody mimetic fusion protein, long-acting C5 inhibitor. It is being evaluated in phase 1 clinical trials for patients with complement-mediated diseases.

                            Brand Name : RLYB116

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 20, 2023

                            Lead Product(s) : RLYB116

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Rallybio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Rallybio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLYB212

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study...

                            Details : RLYB212, an anti-HPA-1a monoclonal antibody and once monthly subcutaneous administration, being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia.

                            Brand Name : RLYB212

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 28, 2023

                            Lead Product(s) : RLYB212

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Rallybio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Rallybio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLYB212

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1...

                            Details : RLYB212 to rapidly accelerate the elimination of HPA-1a positive platelets transfused to HPA-1a negative healthy male participants. It is being developed to prevent fetal and neonatal alloimmune thrombocytopenia.

                            Brand Name : RLYB212

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 24, 2023

                            Lead Product(s) : RLYB212

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Rallybio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Rallybio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLYB211

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the P...

                            Details : RLYB211 is a polyclonal anti-HPA-1a antibody derived from human plasma, it is being investigated for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

                            Brand Name : RLYB211

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 06, 2023

                            Lead Product(s) : RLYB211

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Rallybio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Rallybio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLYB212

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent F...

                            Details : RLYB212 to rapidly accelerate the elimination of HPA-1a positive platelets transfused to HPA-1a negative healthy male participants. It is being developed to prevent fetal and neonatal alloimmune thrombocytopenia.

                            Brand Name : RLYB212

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 06, 2023

                            Lead Product(s) : RLYB212

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Rallybio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Rallybio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLYB114

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Recipient : EyePoint Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio's Inhibitor of Complement Component...

                            Details : The partnership will evaluate sustained delivery of Rallybio’s inhibitor of complement component 5 using EyePoint’s proprietary Durasert technology for sustained intraocular drug delivery. RLYB114 is a C5-targeted Affibody® molecule conjugated to po...

                            Brand Name : RLYB114

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            February 27, 2023

                            Lead Product(s) : RLYB114

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Recipient : EyePoint Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Rallybio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Rallybio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLYB212

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloi...

                            Details : The results demonstrate that low doses of the two HPA-1a-specific antibodies, the polyclonal candidate RLYB211 and the monoclonal candidate RLYB212, are equally effective at rapidly clearing HPA-1a-positive platelets from circulation and preventing alloi...

                            Brand Name : RLYB212

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 15, 2022

                            Lead Product(s) : RLYB212

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Rallybio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Rallybio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-based Therapy

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Discovery Platform

                            Recipient : AbCellera

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Base...

                            Details : Under the terms of the agreement, AbCellera and Rallybio will co-develop up to five rare disease novel antibody-based therapeutic targets, which will be chosen together by both companies.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 01, 2022

                            Lead Product(s) : Antibody-based Therapy

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Discovery Platform

                            Recipient : AbCellera

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth